In the latest trading session,, 0.58 million Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) shares changed hands as the company’s beta touched 0.11. With the company’s most recent per share price at $25.50 changing hands around $4.03 or 18.77% at last look, the market valuation stands at $1.86B. KNSA’s current price is a discount, trading about -10.39% off its 52-week high of $28.15. The share price had its 52-week low at $17.38, which suggests the last value was 31.84% up since then. When we look at Kiniksa Pharmaceuticals International Plc’s average trading volume, we note the 10-day average is 0.56 million shares, with the 3-month average coming to 624.97K.
Analysts gave the Kiniksa Pharmaceuticals International Plc (KNSA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended KNSA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Kiniksa Pharmaceuticals International Plc’s EPS for the current quarter is expected to be 0.27.
Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) trade information
Instantly KNSA is in green as seen in intraday trades today. With action 27.37%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 28.92%, with the 5-day performance at 27.37% in the green. However, in the 30-day time frame, Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) is 10.44% up. Looking at the short shares, we see there were 3.32 million shares sold at short interest cover period of 5.5 days.
The consensus price target for the stock as assigned by Wall Street analysts is 35, meaning bulls need an upside of 27.14% from its recent market value. According to analyst projections, KNSA’s forecast low is 35 with 35 as the target high. To hit the forecast high, the stock’s price needs a -37.25% plunge from its current level, while the stock would need to soar -37.25% for it to hit the projected low.
Kiniksa Pharmaceuticals International Plc (KNSA) estimates and forecasts
Year-over-year growth is forecast to reach 36.47% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 140.79M. 6 analysts are of the opinion that Kiniksa Pharmaceuticals International Plc’s revenue for the current quarter will be 148.04M. The company’s revenue for the corresponding quarters a year ago was 108.63M and 112.21M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 29.60%. The estimates for the next quarter sales put growth at 31.92%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 27.38%. The 2025 estimates are for Kiniksa Pharmaceuticals International Plc earnings to increase by 204.57%.
KNSA Dividends
Kiniksa Pharmaceuticals International Plc is expected to release its next quarterly earnings report on 2025-Feb-24.
Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.03% of Kiniksa Pharmaceuticals International Plc shares while 92.94% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 96.84%. There are 92.94% institutions holding the Kiniksa Pharmaceuticals International Plc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 6.466% of the shares, roughly 4.59 million KNSA shares worth $85.72 million.
FAIRMOUNT FUNDS MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 4.5136% or 3.2 million shares worth $59.83 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 1.16 shares estimated at $29.44 million under it, the former controlled 2.87% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.53% of the shares, roughly 1.02 shares worth around $25.93 million.
